{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Screening Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from a footnote in Section 1.3, Table 1, stating that procedures for US screening sites are detailed in Section 8."
      },
      {
        "id": "ref_2",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference from Section 2.3.1.1 to Section 10.5 for details on COVID-19 vaccine risks and mitigation."
      },
      {
        "id": "ref_3",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference from Table 3 (Potential Risks and Mitigation Strategy) to Section 6.6 for dose modification or discontinuation procedures."
      },
      {
        "id": "ref_4",
        "name": "Adaptive Features Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference from Section 4.1 to Table 4 for a description of adaptive design features."
      },
      {
        "id": "ref_5",
        "name": "Dose Modification Criteria Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference from Table 4 to Table 7 for dose modification criteria."
      },
      {
        "id": "ref_6",
        "name": "Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference from Section 5.3 (Lifestyle Considerations) to Section 5.2 regarding blood donation restrictions."
      },
      {
        "id": "ref_7",
        "name": "Contraception Guidance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference from Section 5.3 to Section 10.4 for details on appropriate contraceptive methods."
      },
      {
        "id": "ref_8",
        "name": "Inclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference from Section 5.3 to Section 5.1 regarding start times for contraceptives."
      },
      {
        "id": "ref_9",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference from Section 7.1 to the SoA for data collection requirements upon study intervention discontinuation."
      },
      {
        "id": "ref_10",
        "name": "Pregnancy Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference from Section 7.1 to Section 8.2.6 regarding discontinuation due to pregnancy."
      },
      {
        "id": "ref_11",
        "name": "QTc Withdrawal Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
        "description": "Reference from Section 8.2.3 to Section 7 for QTc withdrawal criteria."
      },
      {
        "id": "ref_12",
        "name": "Clinical Laboratory Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 8.2.4 to Section 10.2 for the list of clinical laboratory tests to be performed."
      },
      {
        "id": "ref_13",
        "name": "AE/SAE Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Reference from Section 8.3 to Section 10.3 for procedures on recording, evaluating, and reporting AEs and SAEs."
      },
      {
        "id": "ref_14",
        "name": "Lost to Follow-up Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference from Section 8.3.3 to Section 7.3 for the definition of lost to follow-up."
      },
      {
        "id": "ref_15",
        "name": "Genetic Testing Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference from Section 8.3.6 stating that biobanked samples will not be used for genetic testing as detailed in Section 8.7."
      },
      {
        "id": "ref_16",
        "name": "Molybdenum Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference from Section 8.5 to Section 8.1.1 for details on molybdenum measurement in food, drinks, urine, and feces."
      },
      {
        "id": "ref_17",
        "name": "Biomarker Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference from Section 8.8 to Section 8.6 for details on copper and ceruloplasmin biomarkers."
      },
      {
        "id": "ref_18",
        "name": "Analysis Populations Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "Populations for Analysis",
        "description": "Reference from Section 9.3 to Table 8, which defines the population sets for analysis."
      },
      {
        "id": "ref_19",
        "name": "ECG Schedule Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.4.3 to the SoA (Table 1) for ECG time points."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Addition of text to the footnote to state that procedures specific to screening sites (only in the US) detailed in Section 8",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 1.3 Schedule of Activities (SoA), Table 1",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Results obtained from studies of ALXN1840 and ammonium tetrathiomolybdate in participants with WD; see the IB.",
        "annotationType": "Reference",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 2.3.1.1, Table 3",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "Outpatient Period (Day 9 to Day 23) may be extended up to an additional 14 days with Investigator approval with adequate supply of study intervention to support daily dosing can be provided, and with record of exact duration of Outpatient Period is recorded; participants will reinitiate the study on Day 23.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 4.1, Table 4",
        "pageNumber": 27
      },
      {
        "id": "annot_4",
        "text": "In this study, dosing for ALXN1840 will be initiated at 15 mg once daily for a minimum of 4 weeks, with an increase to 30 mg after 4 weeks, unless there are safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may place participants at undue risk, in which case, patients may remain on the 15 mg/day dose for the duration of the study.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 4.1, Table 4",
        "pageNumber": 27
      },
      {
        "id": "annot_5",
        "text": "Samples collected within Â± 10% or 30 min, whichever is less, of the scheduled time will not be considered a protocol deviation.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 8.5 Pharmacokinetics",
        "pageNumber": 49
      },
      {
        "id": "annot_6",
        "text": "Screened: All participants who sign the ICF.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 9.3, Table 8",
        "pageNumber": 51
      },
      {
        "id": "annot_7",
        "text": "Safety Analysis Set: All participants who receive at least 1 dose of ALXN1840 treatment.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 9.3, Table 8",
        "pageNumber": 51
      },
      {
        "id": "annot_8",
        "text": "Per Protocol Set: All participants who received at least 1 dose of ALXN1840, had Baseline and all post Baseline values of copper intake (in food and drink) and copper output (in feces and urine), and were 100% compliant with study drug dosing. Participants with major protocol deviations that are likely to impact the primary endpoint analysis will be excluded from the Per Protocol (PP) Set.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 9.3, Table 8",
        "pageNumber": 51
      },
      {
        "id": "annot_9",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Section 9.4.4 Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Clarify study procedures in the US to facilitate recruitment and lessen inconvenience for participants.",
        "amendmentNumber": "Amendment 3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Previous amendment version.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Previous amendment version.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Previous amendment version.",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_5",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original approved protocol.",
        "amendmentNumber": "N/A"
      }
    ],
    "summary": {
      "referenceCount": 19,
      "annotationCount": 9,
      "versionCount": 5
    }
  }
}